FOXJ2

FOXJ2 is a forkhead-family transcription factor with dual DNA-binding specificity that regulates diverse processes including gametogenesis, epithelial–mesenchymal transition, inflammatory signaling, and chaperone-mediated autophagy by directly activating or repressing target gene promoters. It exists as two isoforms (FHX.L and FHX.S) differing in transactivation potency, localizes constitutively to the nucleus via determinants flanking the forkhead domain, and contains at least three transactivation domains (PMID:10777590, PMID:10966786, PMID:12787665). Validated direct transcriptional targets include E-cadherin/CDH1, Connexin-43/Cx43, LAMP2A, MCU, and Tak1; through these targets FOXJ2 controls cell adhesion, mitochondrial calcium homeostasis, autophagy, and NF-κB/MAPK inflammatory cascades (PMID:30206221, PMID:34914223, PMID:35908066, PMID:40205506, PMID:41498035). Germ-cell-specific Foxj2 knockout causes meiotic arrest with defective chromosomal synapsis and DNA double-strand break repair leading to complete male infertility, while granulosa-cell-specific overexpression drives MCU-dependent mitochondrial calcium overload and apoptosis causing premature ovarian insufficiency (PMID:27316861, PMID:40205506).

1. 2000 High

   Establishing that FOXJ2 is a transcriptional activator with an unusual dual DNA-binding specificity resolved how a single forkhead factor could regulate promoters with divergent binding sites.

   Evidence SELEX and transfection/reporter assays in cultured cells

   PMID:10777590

   Open questions at the time

   • Crystal structure of forkhead domain bound to each site type was not determined
   • Endogenous genomic targets were not identified
2. 2000 High

   Identification of two alternatively spliced isoforms (FHX.L/FHX.S) with different transactivation capacities and tissue-variable ratios provided a mechanism for cell-type-specific modulation of FOXJ2 transcriptional output.

   Evidence Isoform cloning, domain deletion analysis, reporter assays

   PMID:10966786

   Open questions at the time

   • Splicing regulation mechanism not characterized
   • Isoform-specific target gene sets not defined
3. 2000 Medium

   Demonstrating Foxj2 expression specifically in pachytene-to-round spermatids, Sertoli cells, granulosa cells, and preimplantation embryos pointed to roles in gametogenesis and early development before any loss-of-function data existed.

   Evidence RT-PCR and in situ hybridization in mouse tissues and embryos

   PMID:11025217

   Open questions at the time

   • Functional requirement in these cell types was not tested
   • Protein-level expression not confirmed by immunohistochemistry
4. 2003 High

   Systematic mutagenesis mapped nuclear localization determinants to two tyrosines and a basic stretch flanking the forkhead domain, identified three transactivation domains, and showed two phosphoserine residues are dispensable for transactivation, defining the modular architecture of FOXJ2.

   Evidence Deletion/point mutagenesis, nuclear localization assays, reporter assays, phosphorylation mapping

   PMID:12787665

   Open questions at the time

   • Kinase(s) responsible for serine phosphorylation not identified
   • Whether phosphorylation regulates other functions (e.g., DNA binding, protein interactions) not tested
5. 2008 Medium

   Transgenic FOXJ2 overexpression causing embryonic lethality, cardiac hypertrophy, and testicular defects, together with identification of Connexin-43 and E-cadherin as direct promoter targets, established the first in vivo phenotypic consequences and candidate target genes.

   Evidence Transgenic mouse overexpression, EMSA, co-transfection reporter assays

   PMID:18726704

   Open questions at the time

   • Direct promoter binding was shown only by EMSA, not ChIP
   • Phenotypes could reflect non-physiological overexpression levels
6. 2012 Medium

   Foxj2 upregulation in proliferating astrocytes after spinal cord injury and its requirement for LPS-induced inflammatory responses extended FOXJ2 function beyond gametogenesis into neuroinflammation.

   Evidence siRNA knockdown in primary rat astrocytes, immunofluorescence, spinal cord injury model

   PMID:22946994

   Open questions at the time

   • Direct transcriptional targets in astrocytes not identified
   • In vivo loss-of-function in astrocytes not performed
7. 2014 Medium

   Discovery that miR-197 directly targets the FOXJ2 3′UTR, and that FOXJ2 in turn activates cholesterol biosynthesis genes (HMGCR, HMGCS1, IDI1), placed FOXJ2 under post-transcriptional miRNA control and expanded its metabolic target repertoire.

   Evidence 3′UTR luciferase reporter assay, siRNA knockdown, cholesterol measurement

   PMID:25451482

   Open questions at the time

   • Direct binding of FOXJ2 to cholesterol gene promoters not confirmed by ChIP
   • Physiological context for STAT6–miR-197–FOXJ2 axis not established in vivo
8. 2015 Medium

   Gain- and loss-of-function experiments in glioma cells confirmed that FOXJ2 suppresses migration/invasion by upregulating E-cadherin and downregulating vimentin, functionally linking FOXJ2 to epithelial–mesenchymal transition control.

   Evidence Overexpression/knockdown in glioma cells, wound healing and transwell assays

   PMID:25661068

   Open questions at the time

   • Whether FOXJ2 directly represses vimentin transcription was not tested
   • No in vivo tumor model
9. 2016 High

   Germ-cell-specific Foxj2 conditional knockout definitively proved that FOXJ2 is essential for meiotic chromosomal synapsis and DNA double-strand break repair, with loss causing complete male infertility and reduced expression of Rad51, Brca1/2, Tex15, and other meiotic genes.

   Evidence Foxj2 flox/flox; Mvh-Cre conditional knockout mouse, histology, immunofluorescence, RT-PCR

   PMID:27316861

   Open questions at the time

   • Whether FOXJ2 directly binds promoters of DSB repair genes was not tested by ChIP
   • Female fertility phenotype of this knockout not reported
10. 2016 Medium

    FOXJ2 was placed upstream of Notch signaling in TGF-β1-induced EMT: FOXJ2 overexpression inhibited EMT while its knockout promoted EMT by increasing Notch1/NICD, clarifying the signaling hierarchy.

    Evidence FOXJ2 overexpression/knockout in NSCLC cells, Western blot, TGF-β1 treatment

    PMID:27611107

    Open questions at the time

    • Direct transcriptional repression of Notch1 by FOXJ2 not demonstrated
    • Single cancer cell line model
11. 2018 High

    ChIP-based confirmation that FOXJ2 directly binds the CDH1 (E-cadherin) promoter in hepatocellular carcinoma cells, downstream of ARHGAP9, upgraded earlier EMSA-only evidence to direct in vivo promoter occupancy.

    Evidence ChIP assay, luciferase reporter assay, RNA-seq, siRNA knockdown in HCC cells

    PMID:30206221

    Open questions at the time

    • Genome-wide ChIP-seq for FOXJ2 not performed
    • Whether FOXJ2 is sufficient or cooperates with other factors at the CDH1 promoter unclear
12. 2021 Medium

    σ-1R–JNK/p38-dependent nuclear translocation of FOXJ2 driving HECTD1 expression in LPS-stimulated astrocytes revealed a signal-dependent regulatory mechanism for FOXJ2 activity beyond its constitutive nuclear localization.

    Evidence Pharmacological inhibition (BD1047, SP600125, SB203580), immunofluorescence, in vivo astrocyte knockdown

    PMID:33781347

    Open questions at the time

    • Whether JNK/p38 directly phosphorylate FOXJ2 was not tested
    • Whether FOXJ2 directly binds the HECTD1 promoter was not shown by ChIP
13. 2021 Medium

    ChIP-validated direct binding of FOXJ2 to the Connexin-43 promoter in testis, with overexpression causing spermatogenic failure, confirmed Cx43 as a bona fide target and showed that precise FOXJ2 dosage is critical for spermatogenesis.

    Evidence Stra8-Cre conditional knock-in mouse, ChIP-PCR, dual-luciferase reporter assay

    PMID:34914223

    Open questions at the time

    • Mechanism by which Cx43 overexpression disrupts spermatogenesis not elucidated
    • Rescue by Cx43 knockdown not performed
14. 2022 High

    Identification of LAMP2A as a direct FOXJ2 target linked FOXJ2 to chaperone-mediated autophagy: FOXJ2 overexpression activated CMA and caused spermatocyte loss, providing a mechanistic pathway for its gain-of-function meiotic phenotype.

    Evidence Germline-specific conditional knock-in mouse, ChIP-PCR, dual-luciferase reporter assay, TEM, autophagy analysis

    PMID:35908066

    Open questions at the time

    • Whether CMA activation is sufficient or requires concurrent Cx43 upregulation not resolved
    • FOXJ2 binding site in LAMP2A promoter not finely mapped
15. 2025 High

    Direct transcriptional activation of MCU by FOXJ2 in granulosa cells, causing mitochondrial calcium overload and apoptosis leading to premature ovarian insufficiency, established FOXJ2 as a regulator of mitochondrial calcium homeostasis and female fertility.

    Evidence Amh-Cre conditional knock-in mouse, ChIP-PCR, dual-luciferase reporter assay, MCU shRNA rescue, flow cytometry

    PMID:40205506

    Open questions at the time

    • Endogenous FOXJ2 loss-of-function in granulosa cells not tested
    • Whether other mitochondrial targets of FOXJ2 exist not explored
16. 2025 Medium

    Discovery that FOXJ2 directly represses Tak1 transcription to attenuate MAPK/NF-κB inflammatory signaling in macrophages established FOXJ2 as a transcriptional repressor at specific loci and an anti-inflammatory factor.

    Evidence ChIP-PCR, luciferase reporter assay, adenoviral overexpression in LPS-stimulated macrophages

    PMID:41498035

    Open questions at the time

    • Mechanism of repression (co-repressor recruitment, chromatin modification) not characterized
    • In vivo anti-inflammatory role not validated in conditional KO models

• Genome-wide identification of FOXJ2 target genes, the structural basis for its dual binding specificity, and the physiological roles of its two isoforms in vivo remain unresolved.
• No genome-wide ChIP-seq or CUT&RUN data available
• No crystal structure of FOXJ2 forkhead domain
• Isoform-specific knockout models not generated